Skip to main content
. 2023 Feb 2;9:1070497. doi: 10.3389/fmed.2022.1070497

FIGURE 2.

FIGURE 2

Annual revenue for Zevalin over the period 2002–2018, reflecting a steady decline and failure to meet forecasts. Source: Biogen and Spectrum financial reports.